0R15 8884.0068 1.4156% 0R1E 9171.0 0.0% 0M69 None None% 0R2V 255.5 0.3929% 0QYR 1619.0 0.0% 0QYP 434.5 -0.344% 0RUK None None% 0RYA 1600.0 4.5752% 0RIH 195.2 1.3763% 0RIH 195.2 1.3763% 0R1O 225.5 9877.8761% 0R1O None None% 0QFP None None% 0M2Z 255.0 0.2457% 0VSO 33.3 -6.4738% 0R1I None None% 0QZI 596.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 236.3943 1.5483%

Bristol-Myers Squibb Company

Healthcare US BMY

57.415USD
-0.165(0.29%)

Last update at 2024-12-24T16:53:00Z

Day Range

57.0157.58
LowHigh

52 Week Range

48.2573.17
LowHigh

Fundamentals

  • Previous Close 57.58
  • Market Cap106397.60M
  • Volume1434345
  • P/E Ratio13.27
  • Dividend Yield4.59%
  • EBITDA18268.00M
  • Revenue TTM44935.00M
  • Revenue Per Share TTM21.50
  • Gross Profit TTM 36378.00M
  • Diluted EPS TTM3.94

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 7713.00M 8098.00M -6871.00000M 4975.00M 6010.00M
Minority interest -18.00000M -20.00000M 20.00M 21.00M 27.00M
Net income 6327.00M 6994.00M -8995.00000M 3439.00M 4952.00M
Selling general administrative 7808.00M 7688.00M 7661.00M 4871.00M 4551.00M
Selling and marketing expenses 7814.00M 7690.00M 7661.00M 4871.00M 4551.00M
Gross profit 36022.00M 36445.00M 30745.00M 18067.00M 16014.00M
Reconciled depreciation 9595.00M 10023.00M 10380.00M 1746.00M 637.00M
Ebit 10328.00M 10159.00M 5128.00M 5464.00M 5434.00M
Ebitda 19923.00M 20182.00M 14816.00M 6599.00M 6071.00M
Depreciation and amortization 9595.00M 10023.00M 9688.00M 1135.00M 637.00M
Non operating income net other -576.00000M 720.00M 2314.00M -938.00000M 850.00M
Operating income 10328.00M 10159.00M 5128.00M 5464.00M 5118.00M
Other operating expenses 37055.00M 37848.00M 40341.00M 20232.00M 17443.00M
Interest expense 1232.00M 1334.00M 1420.00M 656.00M 183.00M
Tax provision 1368.00M 1084.00M 2124.00M 1515.00M 1021.00M
Interest income 1862.00M 550.00M 71.00M 69.00M 380.00M
Net interest income -1232.00000M -1334.00000M -1420.00000M -656.00000M -183.00000M
Extraordinary items - - - 0.00000M -56.00000M
Non recurring - - - - -
Other items - - - - -
Income tax expense 1368.00M 1084.00M 2124.00M 1515.00M 1031.00M
Total revenue 46159.00M 46385.00M 42518.00M 26145.00M 22561.00M
Total operating expenses 26918.00M 27908.00M 28568.00M 12154.00M 10896.00M
Cost of revenue 10137.00M 9940.00M 11773.00M 8078.00M 6547.00M
Total other income expense net -2615.00000M -2061.00000M -11999.00000M -489.00000M 1075.00M
Discontinued operations - - - - -
Net income from continuing ops 6345.00M 7014.00M -8995.00000M 6490.00M 4947.00M
Net income applicable to common shares 6327.00M 6994.00M -9015.00000M 3439.00M 4920.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 96820.00M 109314.00M 118481.00M 129944.00M 10659.00M
Intangible assets 36355.00M 42775.00M 53243.00M 63969.00M 1091.00M
Earning assets - - - - -
Other current assets 1596.00M 1290.00M 1368.00M 1983.00M 1116.00M
Total liab 65702.00M 73308.00M 80599.00M 78246.00M 7349.00M
Total stockholder equity 31061.00M 35946.00M 37822.00M 51598.00M 14031.00M
Deferred long term liab 2166.00M 4501.00M 5407.00M 6454.00M 468.00M
Other current liab 13106.00M 10109.00M 10241.00M 7888.00M -2064.00000M
Common stock 292.00M 292.00M 292.00M 292.00M 221.00M
Capital stock 292.00M 292.00M 292.00M 292.00M 221.00M
Retained earnings 25503.00M 23820.00M 21281.00M 34474.00M 34065.00M
Other liab 7392.00M 10961.00M 12340.00M 15882.00M 4544.00M
Good will 21149.00M 20502.00M 20547.00M 22488.00M 6538.00M
Other assets 2877.00M 3342.00M 7328.00M 4834.00M 2165.00M
Cash 9123.00M 13979.00M 14546.00M 12346.00M 6911.00M
Cash and equivalents 9123.00M 13979.00M 14546.00M 12346.00M 6911.00M
Total current liabilities 21890.00M 21868.00M 19080.00M 18304.00M 1703.00M
Current deferred revenue 1344.00M 3693.00M 3622.00M 4492.00M 172.00M
Net debt 31594.00M 31617.00M 37127.00M 35192.00M 438.00M
Short term debt 4400.00M 5117.00M 2504.00M 3479.00M 1703.00M
Short long term debt 4264.00M 4948.00M 2340.00M 3346.00M 1703.00M
Short long term debt total 40717.00M 45596.00M 51673.00M 47538.00M 7349.00M
Other stockholder equity 6547.00M 13102.00M 18088.00M 18352.00M -17493.00000M
Property plant equipment 6255.00M 6049.00M 5886.00M 6252.00M 5027.00M
Total current assets 27273.00M 33262.00M 30192.00M 29354.00M 8884.00M
Long term investments 2187.00M 2713.00M 433.00M 767.00M 1775.00M
Net tangible assets -25947.00000M -28236.00000M -35968.00000M -34859.00000M 6402.00M
Short term investments 130.00M 3242.00M 1285.00M 3047.00M 1973.00M
Net receivables 13937.00M 12516.00M 8501.00M 7685.00M 5965.00M
Long term debt 35056.00M 39605.00M 48336.00M 43387.00M 5646.00M
Inventory 2339.00M 2095.00M 2074.00M 4293.00M 1195.00M
Accounts payable 3040.00M 2949.00M 2713.00M 2445.00M 1892.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 57.00M 60.00M 60.00M 100.00M 96.00M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1281.00000M -1268.00000M -1839.00000M -1520.00000M -2762.00000M
Additional paid in capital - - - - -
Common stock total equity 292.00M 292.00M 292.00M 292.00M 221.00M
Preferred stock total equity - - - - -
Retained earnings total equity 25503.00M 23820.00M 21281.00M 34474.00M 34065.00M
Treasury stock - -31259.00000M -26237.00000M -25357.00000M -19574.00000M
Accumulated amortization - - - - -
Non currrent assets other 1037.00M 1655.00M 2084.00M 6604.00M -14027.00000M
Deferred long term asset charges - - - 510.00M 1371.00M
Non current assets total 69547.00M 76052.00M 88289.00M 100590.00M 1775.00M
Capital lease obligations 1397.00M 1043.00M 997.00M 805.00M -
Long term debt total 35056.00M 39605.00M 48336.00M 43387.00M 5646.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 3037.00M 1297.00M 2108.00M -152.00000M 74.00M
Change to liabilities -887.00000M 45.00M -2117.00000M 1136.00M 103.00M
Total cashflows from investing activities -1062.00000M -538.00000M -10859.00000M -9770.00000M -874.00000M
Net borrowings -5311.00000M -6182.00000M 3928.00M 17653.00M -548.00000M
Total cash from financing activities -16962.00000M -16224.00000M -1151.00000M 7621.00M -3535.00000M
Change to operating activities -183.00000M 606.00M 1074.00M 702.00M 634.00M
Net income 6345.00M 7014.00M -8995.00000M 3460.00M 4947.00M
Change in cash -4991.00000M -657.00000M 2153.00M 5909.00M 1490.00M
Begin period cash flow 14316.00M 14973.00M 12820.00M 6911.00M 5421.00M
End period cash flow 9325.00M 14316.00M 14973.00M 12820.00M 6911.00M
Total cash from operating activities 13066.00M 16207.00M 14052.00M 8067.00M 5940.00M
Issuance of capital stock - - - - -
Depreciation 10276.00M 10686.00M 10380.00M 1746.00M 637.00M
Other cashflows from investing activities -2981.00000M -862.00000M -12214.00000M -8782.00000M 3.00M
Dividends paid 4634.00M 4396.00M 4075.00M 2679.00M 2613.00M
Change to inventory -69.00000M 13.00M 2672.00M 463.00M -216.00000M
Change to account receivables -663.00000M -2117.00000M -2951.00000M 1659.00M -267.00000M
Sale purchase of stock -8001.00000M -6287.00000M -1546.00000M -7300.00000M -320.00000M
Other cashflows from financing activities 7104.00M 641.00M 542.00M -53.00000M -54.00000M
Change to netincome -1078.00000M -748.00000M -197.00000M -62.00000M 901.00M
Capital expenditures 1118.00M 973.00M 753.00M 836.00M 951.00M
Change receivables -663.00000M -1054.00000M -646.00000M 752.00M -429.00000M
Cash flows other operating -858.00000M 251.00M 12955.00M 572.00M -3.00000M
Exchange rate changes - - - - -41.00000M
Cash and cash equivalents changes -4958.00000M -555.00000M 2042.00M 5918.00M 1490.00M
Change in working capital -2229.00000M -1253.00000M 983.00M 3065.00M 176.00M
Stock based compensation 457.00M 583.00M 779.00M 441.00M 221.00M
Other non cash items 955.00M 570.00M 9922.00M 279.00M -127.00000M
Free cash flow 11948.00M 15234.00M 13299.00M 7231.00M 4989.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BMY
Bristol-Myers Squibb Company
-0.165 0.29% 57.41 13.27 6.99 2.31 3.66 3.06 7.03
LLY
Eli Lilly and Company
-0.97 0.12% 795.31 103.14 46.73 16.88 48.24 17.43 69.11
JNJ
Johnson & Johnson
0.07 0.05% 145.34 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc
0.86 0.48% 179.25 61.52 14.86 5.62 51.62 6.76 20.58
MRK
Merck & Company Inc
0.03 0.03% 99.39 59.83 12.33 4.50 6.47 4.94 23.79

Reports Covered

Stock Research & News

Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Bristol-Myers Squibb Company

430 East 29th Street, New York, NY, United States, 10016

Key Executives

Name Title Year Born
Dr. Giovanni Caforio M.D. Chairman & CEO 1965
Mr. David V. Elkins Exec. VP & CFO 1968
Ms. Sandra Leung Esq. Exec. VP & Gen. Counsel 1961
Dr. Christopher S. Boerner Exec. VP & Chief Commercialization Officer 1971
Mr. Rupert Vessey BCH, BM, DPHIL, M.A. Exec. VP and Pres of Research & Early Devel. 1965
Mr. Greg Meyers Exec. VP and Chief Digital & Technology Officer 1973
Mr. Timothy Power VP & Head of Investor Relations NA
Ms. Cari Gallman Sr. VP & Chief Compliance and Ethics Officer NA
Ms. Ann M. Powell Judge Exec. VP & Chief HR Officer 1966
Mr. Jitendra Tyagi Head of US Drug Makers - India NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions